MTOR and urinary bladder carcinoma: Jolkinolide B enhances the antitumor efficacy of mTOR inhibitors (temsirolimus, rapamycin, or everolimus) against both PTEN-deficient and cisplatin-resistant bladder cancer cells by suppressing AKT signaling and autophagy [160].